LDN193189

LDN193189 is a small molecule inhibitor that selectively targets bone morphogenetic protein (BMP) type I receptors ALK2 and ALK3. It is commonly used in research settings to study BMP signaling pathways and their role in various biological processes and diseases.

Mechanism of Action

LDN193189 inhibits BMP type I receptors ALK2 and ALK3 by binding to the ATP-binding site of these receptors. This prevents the phosphorylation and activation of Smad proteins, which are the downstream effectors of BMP signaling. As a result, LDN193189 effectively blocks BMP signaling.

Applications in Research

LDN193189 is widely used in research to study the role of BMP signaling in various biological processes and diseases. For example, it has been used to investigate the role of BMP signaling in embryonic development, tissue regeneration, cancer, and fibrosis.

In cancer research, LDN193189 has been used to study the role of BMP signaling in tumor growth and metastasis. It has been found that inhibition of BMP signaling by LDN193189 can suppress tumor growth and metastasis in various types of cancer, including breast cancer, prostate cancer, and lung cancer.

In fibrosis research, LDN193189 has been used to study the role of BMP signaling in the development of fibrosis in various organs, including the liver, kidney, and lung. It has been found that inhibition of BMP signaling by LDN193189 can prevent the development of fibrosis and promote the resolution of existing fibrosis.

Safety and Toxicity

As a research tool, LDN193189 is not intended for human use. Therefore, its safety and toxicity in humans have not been thoroughly evaluated. However, in animal studies, LDN193189 has been found to be well-tolerated with no significant adverse effects reported at the doses commonly used in research.

See Also

• Bone morphogenetic protein
• ALK2
• ALK3
• Smad proteins
• Cancer
• Fibrosis